Table 1 Patient characteristics
Pre-neoadjuvant therapy | |||
|---|---|---|---|
Subtype | ER + / HER2− | HER2 +  | ER−/PR−/HER2− |
n (%) | 20 (58.8%) | 11 (32.4%) | 3 (8.8%) |
Mean Age (years) | 59.5 | 52.6 | 54 |
Range (years) | 31–91 | 28–85 | 43–68 |
Tumour stage | |||
 T1 | 0 | 1 (9%) | 0 |
 T2 | 14 (70%) | 5 (45.5) | 3 (100%) |
 T3 | 3 (15%) | 4 (36.4%) | 0 |
 T4 | 3 (15%) | 1 (9%) | 0 |
Post-neoadjuvant therapy | |||
|---|---|---|---|
n | 2 | 2 | − |
Mean Age (years) | 58.5 | 47.5 | − |
Range | 45–72 | 42–53 |  |
Tumour stage | |||
 T1 | 0 | 0 | 0 |
 T2 | 1 (50%) | 0 | 0 |
 T3 | 1 (50%) | 1 (50%) | 0 |
 T4 | 0 | 1(50 | 0 |